EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Modular Antibody-Based Platform for PD-L1 Pretargeted SPECT Imaging and In Vitro 177Lu Cytotoxicity in a Murine Melanoma Model

Gonzalo Rodríguez, Ximena Camacho, Ana Laura Reyes, Carolina Perroni, Eduardo Savio, Marcelo Fernández, María Moreno, Roger Chammas, Pablo Cabral, Juan Pablo Gambini, Marcos Couto, Hugo Cerecetto und 1 weitere

Molecules · 11.11.2026 · 31 (22) · 4050

DOI: 10.3390/molecules31224050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, online erschienen am 11.11.2026. Verfasst von Gonzalo Rodríguez und 12 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Nacional de Investigación e Innovación, Universidad de la República, PEDECIBA.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Accurate non-invasive assessment of PD-L1 expression and function remains challenging due to tumor heterogeneity and the limitations of conventional biopsy-based studies. Here, we present a modular platform based on atezolizumab for PD-L1 imaging and radiopharmaceutical evaluation in melanoma models. Atezolizumab was functionalized with trans-cyclooctene to allow rapid and selective conjugation, via inverse-demand Diels–Alder, with 99mTc-HYNIC-tetrazine probes, generating in situ a SPECT probe for in vivo studies. In a syngeneic C57BL/6J model with Tm1 cells, pretargeting allowed tumor detection at 4 h with heterogeneous intratumoral uptake; a directly labeled antibody evaluated at the same time point is reported as a reference. Cy5-tetrazine-enabled fluorescence labeling was used for in vitro studies, i.e., flow cytometry and quantitative analysis of PD-L1 status under basal and interferon-γ-stimulated conditions. To analyze PD-L1 as a target for radiotherapy, a conjugate of atezolizumab with lutetium-177, via a DOTA chelator, was developed and evaluated in vitro: at 0.55 MBq, it reduced Tm1 cell viability more than free 177LuCl3, with a greater effect after interferon-γ stimulation, and the effect was further increased in combination with a PARP inhibitor. Using the same antibody for imaging and radionuclide-based cytotoxicity suggests a potential theranostic application, to be validated in vivo. This work describes a modular platform for PD-L1 interrogation that supports further radiopharmaceutical development.

Förderung

  • Agencia Nacional de Investigación e Innovación
  • Universidad de la República
  • PEDECIBA

Zitieren

APA

Rodríguez, G., Camacho, X., Reyes, A. L., Perroni, C., Savio, E., Fernández, M., Moreno, M., Chammas, R., Cabral, P., Gambini, J. P., Couto, M., Cerecetto, H., & García, M. F. (2026). A Modular Antibody-Based Platform for PD-L1 Pretargeted SPECT Imaging and In Vitro 177Lu Cytotoxicity in a Murine Melanoma Model. Molecules, 31(22), 4050. https://doi.org/10.3390/molecules31224050

Vancouver

Rodríguez G, Camacho X, Reyes AL, Perroni C, Savio E, Fernández M, et al. A Modular Antibody-Based Platform for PD-L1 Pretargeted SPECT Imaging and In Vitro 177Lu Cytotoxicity in a Murine Melanoma Model. Molecules. 2026;31(22):4050. doi:10.3390/molecules31224050

BibTeX
@article{Rodrguez2026,
  author = {Rodríguez, Gonzalo and Camacho, Ximena and Reyes, Ana Laura and Perroni, Carolina and Savio, Eduardo and Fernández, Marcelo and Moreno, María and Chammas, Roger and Cabral, Pablo and Gambini, Juan Pablo and Couto, Marcos and Cerecetto, Hugo and García, María Fernanda},
  title = {A Modular Antibody-Based Platform for PD-L1 Pretargeted SPECT Imaging and In Vitro 177Lu Cytotoxicity in a Murine Melanoma Model},
  journal = {Molecules},
  year = {2026},
  volume = {31},
  number = {22},
  pages = {4050},
  doi = {10.3390/molecules31224050}
}
Kostenlos starten →